Ostrum Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Ostrum Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$823K	Sell	1,065 -3,221	-75%	-$2.47M	0.05%	244
2025 Q4	$3.31M	Sell	4,286 -2,145	-33%	-$1.46M	0.16%	97
2025 Q3	$3.62M	Buy	6,431 +753	+13%	+$426K	0.16%	112
2025 Q2	$2.98M	Buy	5,678 +586	+12%	+$327K	0.14%	134
2025 Q1	$3.23M	Buy	5,092 +1,579	+45%	+$1.09M	0.17%	111
2024 Q4	$2.5M	Sell	3,513 -584	-14%	-$490K	0.22%	145
2024 Q3	$4.31M	Sell	4,097 -925	-18%	-$1.03M	0.36%	57
2024 Q2	$5.28M	Buy	5,022 +1,563	+45%	+$1.52M	0.46%	37
2024 Q1	$3.33M	Sell	3,459 -143	-4%	-$136K	0.26%	108
2023 Q4	$3.16M	Buy	3,602 +842	+31%	+$693K	0.28%	110
2023 Q3	$2.27M	Sell	2,760 -2,453	-47%	-$1.93M	0.21%	154
2023 Q2	$3.75M	Sell	5,213 -72	-1%	-$55.5K	0.31%	87
2023 Q1	$4.34M	Buy	+5,285	New	+$3.99M	0.38%	65

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Ostrum Asset Management's REGN Position: Q1 2026 in Review

Ostrum Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 75% in Q1 2026, selling an estimated $2.47M and leaving 1,065 shares worth $823K. The position accounts for 0.05% of the portfolio, ranked #244.

Ostrum Asset Management first reported a position in REGN in Q1 2023 and has held it in 13 quarters since. The position peaked at $5.28M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Ostrum Asset Management held 1,065 shares of Regeneron Pharmaceuticals worth $823K as of Q1 2026.
Ostrum Asset Management sold 3,221 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.47M.
Regeneron Pharmaceuticals made up 0.05% of Ostrum Asset Management's portfolio in Q1 2026, its #244 holding.
Ostrum Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Ostrum Asset Management's Regeneron Pharmaceuticals position peaked at $5.28M in Q2 2024.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Ostrum Asset Management's 13F filing for Q1 2026, filed 14 May 2026.